Czech Academy molecular genetics institute strong in immunology, cancer research, and European bio-infrastructure networks.
The Institute of Molecular Genetics of the Czech Academy of Sciences is a leading Czech research center specializing in molecular biology, genetics, and biomedicine. Their core work spans cancer biology, neurodegenerative diseases, immunology (particularly T-cell biology), and genome editing — translating fundamental genetic research into understanding of human diseases. They also operate as a node in European research infrastructures for mouse disease models, bio-imaging, and chemical biology screening, making their facilities and expertise accessible to the wider research community.
D-FENS explored Dicer-dependent defense mechanisms, SIDSCA linked DNA damage to neurodegeneration, ENHPATHY studied enhancer-driven disease, and Bio4Med trained PhDs in biological bases of human diseases including cancer and brain disease.
FunDiT (their largest grant at EUR 1.7M) focused on functional diversity of T cells, and IMGENE addressed genome editing efficiency — both reflecting deep capacity in immunogenomics.
Active in INFRAFRONTIER2020 (mouse models), EU-OPENSCREEN-DRIVE (chemical biology screening), EOSC-Life (open data cloud), EuBI PPII (bio-imaging), and IPAD-MD (mouse phenotyping) — consistently contributing to pan-European infrastructure.
EU-OPENSCREEN-DRIVE centered on medicinal chemistry and compound screening, while SILIA applied advanced microscopy to study cilia assembly.
ARIB was a Teaming project to build a Czech-German center of excellence, RItrain developed research infrastructure management skills, and Bio4Med was an international doctoral programme.
Algae4IBD (2021-2026) represents a new direction into functional food and inflammatory bowel disease treatment using algae-derived compounds.
In the early H2020 period (2015-2018), the institute focused on foundational molecular biology — PhD training in biomedicine, DNA damage research, and building research management capacity. From 2019 onward, the focus shifted toward functional immunology (T-cell diversity), open science infrastructure (EOSC, chemical screening platforms), and a surprising move into algae-based therapeutics for inflammatory bowel disease. The evolution shows a maturing institute moving from training and capacity-building toward leading its own ambitious research programs and diversifying into translational health applications.
Moving toward translational biomedical research with growing interest in gut health and functional foods, suggesting openness to interdisciplinary and industry-facing collaborations.
The institute balances leadership and partnership roughly evenly — coordinating 5 of 16 projects, including their two largest grants (D-FENS and FunDiT, both ERC-level). As a participant, they consistently join large European infrastructure consortia, suggesting they are a trusted institutional node rather than a one-off contributor. With 175 unique partners across 28 countries, they maintain a broad and diversified network rather than relying on a tight circle of repeat collaborators.
Extensively connected across Europe with 175 unique consortium partners in 28 countries, driven largely by participation in pan-European research infrastructure projects. Their Czech-German cooperation through ARIB suggests particularly strong ties with Germany.
As a Czech Academy of Sciences institute, they combine the depth of a dedicated molecular genetics lab with broad access to European infrastructure networks for mouse models, chemical screening, and bio-imaging. Their dual capacity — running ERC-grade fundamental research while simultaneously serving as a national node for multiple EU research infrastructures — makes them unusually versatile. For consortium builders, they offer both scientific excellence in immunology and genetics AND practical access to shared European research platforms.
